Samantha Caldwell

Samantha Caldwell

Auto-generated profile, based on publicly available information

Samantha Caldwell

Women's Health and Genetics Laboratory Corporation of America La Jolla California USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2020 in Prenatal Diagnosis
Verified
Journal Article
Open access
PDF file
JRJill M. Rafalko
Jill M. Rafalko
SCSamantha Caldwell
Samantha Caldwell
JTJohn Tynan
John Tynan
EAEyad Almasri
Eyad Almasri
VWVivian Weinblatt
Vivian Weinblatt
RMRon McCullough
Ron McCullough
Objective: To examine the relationship between the fraction of cell‐free DNA (cfDNA) affected by aneuploidy compared to the overall fetal fraction of a prenatal screening specimen and its effect on positive predictive value (PPV).Method: CfDNA specimens positive for trisomy 13, 18, and 21 with diagnostic outcomes were analysed over a 22‐month period in one clinical laboratory. For each positive specimen, a “mosaicism ratio” (MR) was calculated by dividing the fraction of cfDNA affected by aneuploidy by the overall fetal fraction of the specimen. PPVs were calculated and analyzed based on various MR ranges.Results: Trisomy 13 was the aneuploidy most commonly seen in mosaic form, followed by trisomy 18 and trisomy 21. Significant differences in positive predictive values were noted for all three trisomies between samples with an MR in the “mosaic” versus “non‐mosaic” range, as well as between results classified as “low‐mosaic” versus “high‐mosaic.”Conclusion: PPVs may be influenced, in part, by the mosaicism ratio associated with a particular result. The data generated from this study may be useful in providing more personalized risk assessments for patients with positive cfDNA screening results.

8 March 2021 in Prenatal Diagnosis
Verified
Journal Article
Open access
PDF file
SCSamantha Caldwell
Samantha Caldwell
EAEyad Almasri
Eyad Almasri
LSLindsey Schmidt
Lindsey Schmidt
CXChen Xu
Chen Xu
BDBrittany Dyr
Brittany Dyr
PCPhilip Cacheris
Philip Cacheris
Objective: To evaluate cell‐free DNA (cfDNA) redraws and pregnancy outcomes following low fetal fraction (FF) cfDNA failures, as it has been suggested that a failed cfDNA screen due to insufficient FF carries increased risk for fetal aneuploidy.Methods: Here >200,000 consecutive samples were reviewed and >1,100 patients were identified with a failed cfDNA due to low FF using genome‐wide massively parallel sequencing. Redraw results following the initial low FF failure were analyzed, as well as pregnancy outcomes for patients with repeated low FF failure on redraw.Results: Upon redraw 84.2% of samples yielded a reportable result with no enrichment of aneuploidy observed (p = 0.332). Higher maternal weights and multifetal pregnancy rates were observed in samples with insufficient FF. In patients with repeated low FF failure on redraw, almost all pregnancies resulted in apparently healthy liveborns.Conclusion: Insufficient FF was not an indicator of aneuploidy risk or adverse pregnancy outcomes in this study. Caution should be taken in generalizing aneuploidy risk to all low FF cfDNA failures. Redrawing may be an appropriate next step, as proceeding directly with diagnostic testing for aneuploidy may be unwarranted for most patients.

15 August 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
SCSamantha Caldwell
Samantha Caldwell
KSKatelynn Sagaser
Katelynn Sagaser
ZNZoe Nelson
Zoe Nelson
JFJennifer Frey
Jennifer Frey
JWJenna Wardrop
Jenna Wardrop
SSStuart Schwartz
Stuart Schwartz